You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中智藥業(03737.HK)中期純利升22.1%至7200萬元 每股派息5.15港仙
格隆匯 08-26 22:31

格隆匯8月26日丨中智藥業(03737.HK)發佈公告,截至2020年6月30日止6個月,公司收益約為人民幣7.38億元,同比增加約16.0%;毛利約為人民幣4.58億元,同比增加約16.7%;毛利率與上年同期相較增加約0.3個百分點至約62.1%;公司擁有人應占利潤約為人民幣7200萬元,同比增加約22.1%;每股基本盈利約為人民幣8.6分,中期股息每股普通股3.7港仙及特別股息每股普通股1.45港仙。

源自制藥的收益增長約12.1%至3.97億元,並佔報告期間總收益的53.8%,此乃由於集團致力於草晶華品牌打造及投資其分銷管道等現有及新銷售管道而導致銷售有所增長所致。

於2020年6月30日,集團於中山市擁有335間自營連鎖藥店(於2019年6月30日:316間),其中298間為醫保定點藥店。同時於今年開始嘗試加盟的經營模式。

集團將草晶華破壁草本(中藥破壁飲片)的開發作為其核心發展方向,今年上半年,在ISO/TC249WG2第18次(遠端)會議上,獲得工作組同意推薦專案啟動NP投票;並通過ISO/TC249內部投票,同意啟動NP投票。標誌着由公司主導的全球首個關於中藥破壁產品的國際標準建設已進入實質工作階段。接下來,公司將繼續圍繞新型飲片、中成藥、保健食品及SC系列標準方向進行新產品開發和現有產品升級研究,響應國家領導的要求,持續把中藥國際化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account